BioCentury

7:00 AM GMT, Apr 29, 2002
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Delaying gratification with Erbitux

Merck KGaA's decision to delay submission of an MAA for Erbitux cetuximab may end up getting it to market almost as fast and with a broader indication, due to quirks in the European regulatory system.

After a recent meeting to assess

Read the full 408 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.